169 related articles for article (PubMed ID: 20669265)
1. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
3. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
4. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W
Eur J Neurol; 2013 Jan; 20(1):180-7. PubMed ID: 22845710
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole extended release in Parkinson's disease.
Hametner EM; Seppi K; Poewe W
Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
8. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Perez Lloret S; Rascol O
Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial.
Mizuno Y; Yamamoto M; Kuno S; Hasegawa K; Hattori N; Kagimura T; Sarashina A; Rascol O; Schapira AH; Barone P; Hauser RA; Poewe W;
Clin Neuropharmacol; 2012; 35(4):174-81. PubMed ID: 22801294
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
Shen T; Ye R; Zhang B
Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole extended release: in Parkinson's disease.
Chwieduk CM; Curran MP
CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
Kieburtz K;
Mov Disord; 2011 Jan; 26(1):37-44. PubMed ID: 20925067
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Viallet F; Pitel S; Lancrenon S; Blin O
Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073
[TBL] [Abstract][Full Text] [Related]
15. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
16. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
Schapira AH; Albrecht S; Barone P; Comella CL; McDermott MP; Mizuno Y; Poewe W; Rascol O; Marek K
Mov Disord; 2010 Aug; 25(11):1627-32. PubMed ID: 20544810
[TBL] [Abstract][Full Text] [Related]
17. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
20. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
Rascol O; Azulay JP; Blin O; Bonnet AM; Brefel-Courbon C; Césaro P; Damier P; Debilly B; Durif F; Galitzky M; Grouin JM; Pennaforte S; Villafane G; Yaici S; Agid Y
Mov Disord; 2010 Feb; 25(3):368-76. PubMed ID: 20063435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
